### Reference

**Reference:** 085

**Intervention:** Tiotropium Respimat® (Spiriva® Respimat®) 2.5 micrograms inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) in adults. (Tiotropium is a long acting muscarinic antagonist [LAMA]).

**Date of Decision:** June 2018  
**Date of Issue:** June 2018

**Recommendation:** GREEN – can be prescribed within agreed criteria for use in primary or secondary care

### Further Information

- The tiotropium Respimat® 2.5mg inhaler device is accepted as an option for use in South East London in line with its licence as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).
- In line with the local COPD pathway, tiotropium Respimat may be considered as an initial regular therapy in patients who experience breathlessness despite acute treatment with an as required inhaled short acting beta agonist (SABA).
- Tiotropium Respimat is an aerosol spray inhaler device and may be a preferred option for patients without the inspiratory capacity to activate a dry powder inhaler (DPI) device.
- Some patients may find the Respimat device more difficult to use than the DPI products because of the priming and administration steps. The device chosen should be based on patient factors, such as inhaler technique.
- All patients should be asked to demonstrate their inhaler technique regularly and adherence should be established before stepping up therapy.
- The local COPD pathway will be updated to reflect the addition of tiotropium Respimat as a single component inhaled LAMA treatment option.

### Shared Care/ Transfer of care required:

N/A

### Cost Impact for agreed patient group

- As the cost of tiotropium Respimat is currently lower than all other long acting muscarinic antagonist (LAMA) single component inhalers, this formulary inclusion is not expected to have a significant cost impact and may be cost saving.

### Usage Monitoring & Impact Assessment

**Trusts**

- Monitor and submit usage and audit data on request to the APC.

**CCGs**

- Monitor EPACT data and audit against the COPD guidelines
- Exception reports from GPs if inappropriate prescribing requests are made to primary care.

### Evidence reviewed

<table>
<thead>
<tr>
<th>References (from evidence evaluation)</th>
</tr>
</thead>
</table>

### NOTES:

a) Area Prescribing Committee recommendations and minutes are available publicly via the APC website.

b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.

c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS